OncoResponse
2015
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$40M
LATEST DEAL AMOUNT
16
INVESTORS
Description
Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's technology leverages the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, providing a larger number of cancer patients with the benefit of immunotherapy.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 909 Fannin Street
- Suite 2100
- Houston, TX 77024
- United States
+1 (206) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore OncoResponse’s full profile, request a free trial.
OncoResponse Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 11-Sep-2018 | $40M | 000.00 | 0000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series A) | 23-Mar-2017 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 1. Joint Venture | 06-Oct-2015 | Completed | Generating Revenue |
OncoResponse Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
OncoResponse Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 000000000 | 07-Nov-2017 | 000000000000000000 | Biotechnology | 00000000 000000 |
OncoResponse Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Qatar Investment Authority | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | ||
| Redmile Group | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Alexandria Real Estate Equities | Real Estate | Minority | 000 0000 | 000000 0 | ||
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
OncoResponse Executive Team (4)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Clifford Stocks | Co-Founder, Chief Executive Officer & Board Member | ||
| Russ Hawkinson | Chief Financial Officer | ||
| Anil Singhal Ph.D | Chief Scientific Officer |
1 Former Executive
You’re viewing 3 of 4 executives. Get the full list »OncoResponse Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alan Ginsberg | OncoResponse | Board Member | 000 0000 | |
| Andrew Perlman | GreatPoint Ventures | Board Member | 000 0000 | |
| Clifford Stocks | OncoResponse | Co-Founder, Chief Executive Officer & Board Member | 000 0000 | |
| John McKearn Ph.D | RiverVest Venture Partners | Board Member | 000 0000 | |
| Nathan Jorgensen | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 9 board members. Get the full list »